CN108137605A - Acp-196的晶型及其制备方法和药物组合物 - Google Patents

Acp-196的晶型及其制备方法和药物组合物 Download PDF

Info

Publication number
CN108137605A
CN108137605A CN201680060384.3A CN201680060384A CN108137605A CN 108137605 A CN108137605 A CN 108137605A CN 201680060384 A CN201680060384 A CN 201680060384A CN 108137605 A CN108137605 A CN 108137605A
Authority
CN
China
Prior art keywords
acp
crystal form
solvent
crystal
solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201680060384.3A
Other languages
English (en)
Other versions
CN108137605B (zh
Inventor
盛晓红
盛晓霞
朱涛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SOLIPHARMA LLC
Original Assignee
SOLIPHARMA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SOLIPHARMA LLC filed Critical SOLIPHARMA LLC
Priority to CN202110646066.8A priority Critical patent/CN113416194A/zh
Publication of CN108137605A publication Critical patent/CN108137605A/zh
Application granted granted Critical
Publication of CN108137605B publication Critical patent/CN108137605B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

ACP‑196的晶型，晶型的制备方法，其药物组合物及其在制备用于治疗和/或预防布鲁顿酪氨酸激酶(BTK)介导的病症如自身免疫性疾病或病症、异种免疫性疾病或病症、癌症包括淋巴瘤以及炎性疾病或病症的药物中的用途，与已知的ACP‑196固体形式相比，所述晶型在结晶度方面具有优势。

Description

PCT国内申请，说明书已公开。

Claims (12)

  1. PCT国内申请，权利要求书已公开。
CN201680060384.3A 2016-10-05 2016-10-05 Acp-196的晶型及其制备方法和药物组合物 Active CN108137605B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110646066.8A CN113416194A (zh) 2016-10-05 2016-10-05 Acp-196的晶型及其制备方法和药物组合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2016/101430 WO2018064797A1 (zh) 2016-10-05 2016-10-05 Acp-196的晶型及其制备方法和药物组合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110646066.8A Division CN113416194A (zh) 2016-10-05 2016-10-05 Acp-196的晶型及其制备方法和药物组合物

Publications (2)

Publication Number Publication Date
CN108137605A true CN108137605A (zh) 2018-06-08
CN108137605B CN108137605B (zh) 2021-07-13

Family

ID=61830797

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110646066.8A Pending CN113416194A (zh) 2016-10-05 2016-10-05 Acp-196的晶型及其制备方法和药物组合物
CN201680060384.3A Active CN108137605B (zh) 2016-10-05 2016-10-05 Acp-196的晶型及其制备方法和药物组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202110646066.8A Pending CN113416194A (zh) 2016-10-05 2016-10-05 Acp-196的晶型及其制备方法和药物组合物

Country Status (3)

Country Link
US (2) US10899767B2 (zh)
CN (2) CN113416194A (zh)
WO (1) WO2018064797A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112028896A (zh) * 2020-10-14 2020-12-04 奥锐特药业(天津)有限公司 阿卡替尼的新晶型及其制备方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113416194A (zh) 2016-10-05 2021-09-21 杭州领业医药科技有限公司 Acp-196的晶型及其制备方法和药物组合物
WO2018229613A1 (en) * 2017-06-13 2018-12-20 Dr. Reddy's Laboratories Limited Solid forms of acalabrutinib and process for preparation thereof
WO2019041026A1 (en) 2017-08-29 2019-03-07 Apotex Inc. NEW CRYSTALLINE FORMS OF ACALABRUTINIB
KR20200106511A (ko) 2018-01-05 2020-09-14 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. 아칼라브루티닙의 신규 결정형 및 그 제조방법 및 용도
WO2019159097A1 (en) * 2018-02-14 2019-08-22 Sun Pharmaceutical Industries Limited Crystalline polymorphic forms of acalabrutinib
US20210087195A1 (en) * 2018-04-26 2021-03-25 Crystal Pharmaceutical (Suzhou) Co., Ltd. New crystal form of acalbrutinib, preparation method therefor and use thereof
EP3587421A1 (en) 2018-06-29 2020-01-01 Sandoz AG Crystalline forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-alpha]pyrazin-1-yl-n-(pyridin-2-yl)benzamide
CA3048036A1 (en) 2018-07-02 2020-01-02 Apotex Inc Novel crystalline form of ribociclib succinate
WO2020053795A2 (en) 2018-09-13 2020-03-19 Fresenius Kabi Oncology Ltd. Process for the preparation of acalabrutinib and its intermediates
EP3830091A1 (en) 2018-09-25 2021-06-09 Cipla Limited Novel polymorphs of acalabrutinib, a bruton's tyrosine kinase inhibitor
WO2020141562A1 (en) * 2019-01-04 2020-07-09 Msn Laboratories Private Limited, R&D Center Novel crystalline forms and process for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl)}-n-(pyridine-2-yl)benzamide
EP3947386A1 (en) * 2019-03-27 2022-02-09 Assia Chemical Industries Ltd Solid state forms of acalabrutinib
WO2021135346A1 (zh) * 2019-12-31 2021-07-08 苏州科睿思制药有限公司 Acalabrutinib的新晶型及其制备方法和用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014071109A1 (en) * 2012-11-01 2014-05-08 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
CN103889987A (zh) * 2011-07-19 2014-06-25 默沙东有限责任公司 作为btk-抑制剂的4-咪唑并哒嗪-1-基-苯甲酰胺类和4-咪唑并三嗪-1-基-苯甲酰胺类
WO2015110923A2 (en) * 2014-01-21 2015-07-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
WO2015181633A2 (en) * 2014-04-11 2015-12-03 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinase
WO2015185998A2 (en) * 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
EP3317281B1 (en) * 2015-07-02 2020-04-22 Acerta Pharma B.V. Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
CN113416194A (zh) 2016-10-05 2021-09-21 杭州领业医药科技有限公司 Acp-196的晶型及其制备方法和药物组合物
US10899770B2 (en) * 2017-02-20 2021-01-26 Hangzhou Solipharma Co., Ltd. Crystal form of ACP-196 salt and preparation method, pharmaceutical composition, and use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103889987A (zh) * 2011-07-19 2014-06-25 默沙东有限责任公司 作为btk-抑制剂的4-咪唑并哒嗪-1-基-苯甲酰胺类和4-咪唑并三嗪-1-基-苯甲酰胺类
WO2014071109A1 (en) * 2012-11-01 2014-05-08 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2015110923A2 (en) * 2014-01-21 2015-07-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
WO2015181633A2 (en) * 2014-04-11 2015-12-03 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinase
WO2015185998A2 (en) * 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112028896A (zh) * 2020-10-14 2020-12-04 奥锐特药业(天津)有限公司 阿卡替尼的新晶型及其制备方法

Also Published As

Publication number Publication date
US11919906B2 (en) 2024-03-05
CN113416194A (zh) 2021-09-21
US20210188859A1 (en) 2021-06-24
CN108137605B (zh) 2021-07-13
US20190382405A1 (en) 2019-12-19
US10899767B2 (en) 2021-01-26
WO2018064797A1 (zh) 2018-04-12

Similar Documents

Publication Publication Date Title
CN108137605A (zh) Acp-196的晶型及其制备方法和药物组合物
US8227477B2 (en) Nilotinib HCl crystalline forms
RU2673889C1 (ru) Стабильная кристаллическая форма ii апремиласта, не содержащая сольваты, и способ ее получения
CN110312723A (zh) Acp-196盐的晶型、其制备方法、药物组合物和用途
JP2022531969A (ja) 癌を治療するためのＲａｆ阻害剤としてのＮ－（３－（２－（２－ヒドロキシエトキシ）－６－モルホリノピリジン－４－イル）－４－メチルフェニル）－２－（トリフルオロメチル）イソニコチンアミドの新規な結晶形態
CN104736538B (zh) 一种抑制剂的晶型及其制备方法和用途
WO2011095059A1 (zh) 达沙替尼多晶型物及其制备方法和药物组合物
KR20090107013A (ko) 티아졸리딘디온 화합물의 결정질 형태 및 이의 제조 방법
AU2015330554A1 (en) Crystal form of bisulfate of JAK inhibitor and preparation method therefor
JP2018522945A (ja) ビラスチンの結晶形態及びそれらの調製方法
KR102477065B1 (ko) 1-(3-tert-부틸-1-p-톨릴-1H-피라졸-5-일)-3-(5-플루오로-2-(1-(2-하이드록시에틸)-1H-인다졸-5-일옥시)벤질)우레아 하이드로클로라이드의 결정 형태
JP7295025B2 (ja) （ｓ）－［２－クロロ－４－フルオロ－５－（７－モルホリン－４－イルキナゾリン－４－イル）フェニル］－（６－メトキシ－ピリダジン－３－イル）メタノールの結晶性形態
TW201925190A (zh) 嘧啶基胺基─吡唑化合物之多晶型物及固體形式及製備方法
US20200216427A1 (en) Solid state forms of entrectinib
CZ20031397A3 (cs) Nové krystalické a solvatované formy ondansetron hydrochloridu a způsoby jejich přípravy
US9458149B2 (en) Crystal form of dabrafenib and preparation method and use thereof
CN110234639A (zh) 替吡法尼的晶型及其制备方法及药物组合物
CN106496234B (zh) 结晶形态的***[4,5-d]嘧啶化合物及其制备方法和用途
WO2022253261A1 (zh) Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途
CN105949183B (zh) 阿齐沙坦酯的晶型及其制备方法
WO2023280272A1 (zh) 伊沃替尼和其盐的晶型及其制备方法和用途
WO2021176216A1 (en) Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1h-pyrazol-4-yl)-3h-imidazo[4,5-b]pyridine
WO2018054359A1 (zh) 一种喹唑啉衍生物的盐、其制备方法及应用
CN116239568A (zh) 5-ht1f受体激动剂的新晶型及其制备方法
CN105193728A (zh) 一种治疗男性阳痿的药物他达拉非组合物干混悬剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant